CN110664735A - Platelet-rich gel and preparation method thereof - Google Patents
Platelet-rich gel and preparation method thereof Download PDFInfo
- Publication number
- CN110664735A CN110664735A CN201910984321.2A CN201910984321A CN110664735A CN 110664735 A CN110664735 A CN 110664735A CN 201910984321 A CN201910984321 A CN 201910984321A CN 110664735 A CN110664735 A CN 110664735A
- Authority
- CN
- China
- Prior art keywords
- platelet
- thrombin
- rich
- ethylene diamine
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000001879 gelation Methods 0.000 title description 2
- 108090000190 Thrombin Proteins 0.000 claims abstract description 37
- 229960004072 thrombin Drugs 0.000 claims abstract description 37
- 239000012266 salt solution Substances 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 23
- BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004623 platelet-rich plasma Anatomy 0.000 claims abstract description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 16
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 14
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 14
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 14
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000008227 sterile water for injection Substances 0.000 claims abstract description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 8
- 230000002093 peripheral effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 28
- 208000025865 Ulcer Diseases 0.000 description 18
- 231100000397 ulcer Toxicity 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000008960 Diabetic foot Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002266 amputation Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000009979 Traumatic Amputation Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a platelet-rich gel and a preparation method thereof, wherein the preparation method comprises the following steps: preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting the pH value of the sterilized water for injection to 7.8, then adding sodium ethylene diamine tetracetate, and uniformly mixing to obtain a sodium ethylene diamine tetracetate salt solution with the molar concentration of 0.25 mol/L; collecting peripheral venous blood of a patient by using a container filled with an ethylene diamine tetraacetic acid disodium salt solution, and centrifuging to obtain platelet-rich plasma; uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1ml of 10% calcium gluconate to prepare thrombin solution; and uniformly mixing the platelet-rich plasma and the thrombin solution according to the volume ratio of 10:1 to prepare the platelet-rich gel. The platelet-rich gel has good therapeutic effect, and can effectively promote wound healing and shorten treatment time.
Description
Technical Field
The invention relates to the technical field of platelet-rich gel, in particular to platelet-rich gel and a preparation method thereof.
Background
With the social progress and the change of life and dietary style of people, the incidence of diabetes mellitus is increased year by year. The recent epidemiological research result in China shows that the prevalence rate of diabetes in China reaches 9.7 percent, which is higher than the average level in the world by 6.4 percent. The diabetic patients can cause the damage and the malformation of foot soft tissues and bone joint systems due to the combination of peripheral neuropathy and peripheral vascular diseases with overhigh mechanical pressure, thereby causing a series of foot problems from mild neurological symptoms to severe ulcer, infection, vascular diseases, Charcot joint diseases and neuropathic fracture. If active treatment fails to adequately address the symptoms and complications of the lower extremities, catastrophic results can result. Diabetic foot is the leading cause of the most serious complications of diabetes and non-traumatic amputations. With the development of the aging population of China, the incidence rate of diabetic feet is increased year by year, amputation or death is unlikely to occur when the treatment is carried out, and 85 percent of amputation is caused by ulcer. The occurrence of diabetic foot ulcers reduces the quality of life of diabetic patients, prolongs hospitalization time, and brings huge economic burden to society and families, and therefore, it would be of great significance to develop early prevention and treatment of foot problems in diabetic patients.
Currently, with the development of technology and the increased awareness of people about diabetic foot ulcers, more and more methods are applied clinically. The externally applied medicine generally adopted clinically at present achieves the purpose of treatment by sterilizing, improving microcirculation, accelerating the shedding of necrotic tissues, promoting the growth of granulation tissues and repairing ulcer wounds. However, the existing external medicine has general treatment effect, and the time for healing the ulcer is long after the external medicine is used. At present, few solutions which are prepared by adopting autologous peripheral blood and are enriched with platelets are used for treating diabetic ulcers, but the prepared solutions have short retention time on the surfaces of the ulcers and cannot be adhered to wound surfaces, so that the treatment effect is poor.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a platelet-rich gel and a preparation method thereof, and the platelet-rich gel can effectively solve the problems of poor treatment effect and long ulcer healing time of the existing medicines in the aspect of treating diabetic ulcers.
In order to achieve the purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
a preparation method of a platelet rich gel comprises the following steps:
(1) preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting pH to 7.5-8.2, adding sodium ethylene diamine tetracetate, and mixing to obtain sodium ethylene diamine tetracetate solution with molar concentration of 0.2-0.5 mol/L;
(2) collecting peripheral venous blood of a patient by using a container filled with the sodium ethylene diamine tetracetate salt solution prepared in the step (1), and centrifuging to prepare platelet-rich plasma;
(3) uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1-2ml of 10% calcium gluconate to prepare thrombin solution;
(4) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 8-12:1 to prepare platelet-rich gel.
Further, in the step (1), sodium hydrogencarbonate was added to the sterilized water for injection to adjust the pH of the sterilized water for injection to 7.8.
Further, the molar concentration of the ethylenediaminetetraacetic acid sodium salt in the solution prepared in step (1) was 0.25 mol/L.
Further, when blood is collected in the step (2), the collection is stopped when the volume ratio of the EDTA salt solution to the venous blood reaches 1: 8-12.
Further, when blood is collected in the step (2), the collection is stopped when the volume ratio of the EDTA salt solution to the venous blood reaches 1: 10.
Further, the preparation process of the platelet rich plasma in the step (2) is as follows: centrifuging container containing venous blood at 2500r/min for 3-4min, transferring supernatant plasma and liquid 1mm below the plasma into another centrifuge tube, centrifuging the centrifuge tube at 4000r/min for 5-7min, and discarding supernatant.
Further, in the step (3), 1ml of 10% calcium gluconate is mixed according to the proportion of each 1000U of thrombin freeze-dried powder to prepare the thrombin gel.
Further, the platelet-rich plasma and the thrombin solution in the step (4) are mixed uniformly according to the volume ratio of 10:1 to prepare the platelet-rich gel.
The platelet-rich gel is prepared by the preparation method.
The application of the platelet-rich gel in treating diabetic ulcer is provided.
The technical scheme of the invention has the following beneficial effects:
the platelet-rich plasma prepared by the invention contains a large amount of growth factors, and the growth factors are mixed with thrombin solution to prepare gel which is applied to the surface of the ulcer, and the large amount of growth factors can promote the cell renewal of the surface of the ulcer, promote the healing of damaged tissues and induce the regeneration of blood vessels, thereby achieving the treatment effect on the wound and shortening the time for healing the wound.
The invention uses the sodium ethylene diamine tetracetate salt solution with the concentration of 0.2-0.5mol/L as the anticoagulant, the anticoagulation effect is favorable for twice centrifugation of collected peripheral blood to prepare platelet-rich plasma, and the platelet-rich gel is formed after the coagulation promotion of the mixed thrombin and calcium agent, is favorable for adhering to the surface of ulcer to play a role in treatment, and can avoid the prepared gel from stimulating the ulcer wound surface of a patient and reduce the pain of the patient.
Detailed Description
Example 1
A platelet rich gel is prepared by the following steps:
(1) preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting the pH value of the sterilized water for injection to 7.5, then adding sodium ethylene diamine tetracetate, and uniformly mixing to obtain a sodium ethylene diamine tetracetate salt solution with the molar concentration of 0.2 mol/L;
(2) collecting peripheral venous blood of a patient by using a container filled with an ethylenediaminetetraacetic acid disodium salt solution, stopping collecting when the volume ratio of the ethylenediaminetetraacetic acid disodium salt solution to the collected blood in the container is 1:8, putting the container into a centrifugal machine, centrifuging for 3min at the rotating speed of 2500r/min, transferring upper plasma and liquid 1mm below the plasma into another centrifugal tube, centrifuging the centrifugal tube for 5min at the rotating speed of 4000r/min, and discarding supernatant liquid to obtain platelet-rich plasma;
(3) uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1ml of 10% calcium gluconate to prepare thrombin solution;
(4) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 8:1 to prepare platelet-rich gel.
Example 2
A platelet rich gel is prepared by the following steps:
(1) preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting the pH value of the sterilized water for injection to 8.2, then adding sodium ethylene diamine tetracetate, and uniformly mixing to obtain a sodium ethylene diamine tetracetate salt solution with the molar concentration of 0.5 mol/L;
(2) collecting peripheral venous blood of a patient by using a container filled with an ethylenediaminetetraacetic acid disodium salt solution, stopping collecting when the volume ratio of the ethylenediaminetetraacetic acid disodium salt solution to the collected blood in the container is 1:12, putting the container into a centrifugal machine, centrifuging for 4min at the rotating speed of 2500r/min, transferring upper plasma and liquid 1mm below the plasma into another centrifugal tube, centrifuging the centrifugal tube for 7min at the rotating speed of 4000r/min, and discarding supernatant liquid to obtain platelet-rich plasma;
(3) uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1ml of 10% calcium gluconate to prepare thrombin solution;
(4) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 12:1 to prepare platelet-rich gel.
Example 3
A platelet rich gel is prepared by the following steps:
(1) preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting the pH value of the sterilized water for injection to 7.8, then adding sodium ethylene diamine tetracetate, and uniformly mixing to obtain a sodium ethylene diamine tetracetate salt solution with the molar concentration of 0.25 mol/L;
(2) collecting peripheral venous blood of a patient by using a container filled with an ethylenediaminetetraacetic acid disodium salt solution, stopping collecting when the volume ratio of the ethylenediaminetetraacetic acid disodium salt solution to the collected blood in the container is 1:10, putting the container into a centrifugal machine, centrifuging for 4min at the rotating speed of 2500r/min, transferring upper-layer plasma and liquid 1mm below the plasma into another centrifugal tube, centrifuging the centrifugal tube for 6min at the rotating speed of 4000r/min, and removing supernatant to obtain platelet-rich plasma;
(3) uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1ml of 10% calcium gluconate to prepare thrombin solution;
(4) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 10:1 to prepare platelet-rich gel.
Comparative example
A platelet rich gel is prepared by the following steps:
(1) collecting peripheral venous blood of a patient by using a container, putting the container into a centrifuge, centrifuging for 4min at the rotating speed of 2500r/min, transferring upper plasma and liquid which is 1mm below the plasma into another centrifuge tube, centrifuging the centrifuge tube at the rotating speed of 4000r/min for 6min, and discarding supernatant to obtain platelet-rich plasma;
(2) taking thrombin freeze-dried powder and normal saline, and uniformly mixing the thrombin freeze-dried powder and the normal saline according to the proportion that every 1000U of thrombin freeze-dried powder corresponds to 1ml of normal saline to prepare thrombin solution;
(3) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 10:1 to prepare platelet-rich gel.
Test examples
Randomly searching 25 patients with diabetic ulcer, randomly dividing into 5 groups of 5 persons, measuring and recording ulcer area of each patient, recording total ulcer area of each group of patients, and treating the patients with the gel of examples 1-3, the conventional drug dressing and the gel of the comparative example respectively, wherein the treatment method comprises the following steps: spraying the platelet-rich gel on the surface of ulcer or injecting into sinus, covering with sterilized vaseline gauze, wrapping the outer layer with sterile gauze, and repeating the treatment every 3 days. The total area of the ulcer was measured and recorded for each group of patients and the healing rate was calculated for each of 3 days, 6 days, 12 days and 18 days of treatment, and the specific results are shown in table 1.
Percent healing (%) - (area of ulcer before treatment-area of ulcer after treatment)/area of ulcer before treatment × 100%
Table 1: ulcer area recording table for each group of patients
As can be seen from the above table, the platelet rich gels prepared according to the methods of examples 1-3 of the present invention have a very good therapeutic effect on diabetic ulcers, and after 18 days of treatment, the therapeutic rate is over 75%, which is higher than that of conventional drugs and that of the gel in comparative example, especially the gel in example 3 has the best therapeutic effect.
Claims (10)
1. A preparation method of a platelet rich gel is characterized by comprising the following steps:
(1) preparing a sodium ethylene diamine tetracetate salt solution: adding sodium bicarbonate into sterilized water for injection, adjusting pH to 7.5-8.2, adding sodium ethylene diamine tetracetate, and mixing to obtain sodium ethylene diamine tetracetate solution with molar concentration of 0.2-0.5 mol/L;
(2) collecting peripheral venous blood of a patient by using a container filled with the sodium ethylene diamine tetracetate salt solution prepared in the step (1), and centrifuging to prepare platelet-rich plasma;
(3) uniformly mixing thrombin freeze-dried powder and 10% calcium gluconate according to the proportion that each 1000U of thrombin freeze-dried powder corresponds to 1-2ml of 10% calcium gluconate to prepare thrombin solution;
(4) and (3) uniformly mixing the platelet-rich plasma prepared in the step (2) and the thrombin solution prepared in the step (3) according to the volume ratio of 8-12:1 to prepare platelet-rich gel.
2. The method according to claim 1, wherein the pH of the sterilized water for injection is adjusted to 7.8 by adding sodium bicarbonate to the sterilized water for injection in the step (1).
3. The method according to claim 1, wherein the molar concentration of the sodium salt of ethylenediaminetetraacetic acid in the solution obtained in step (1) is 0.25 mol/L.
4. The method according to claim 1, wherein the collection is stopped when the volume ratio of the edta salt solution to the venous blood reaches 1:8-12 when the blood is collected in step (2).
5. The method according to claim 4, wherein the collection is stopped when the volume ratio of the EDTA salt solution to the venous blood reaches 1:10 when the blood is collected in step (2).
6. The method according to claim 1, wherein the platelet-rich plasma in the step (2) is prepared by the following process: centrifuging container containing venous blood at 2500r/min for 3-4min, transferring supernatant plasma and liquid 1mm below the plasma into another centrifuge tube, centrifuging the centrifuge tube at 4000r/min for 5-7min, and discarding supernatant.
7. The method according to claim 1, wherein the thrombin gel is prepared by mixing 1ml of 10% calcium gluconate per 1000U of thrombin lyophilized powder in step (3).
8. The method according to claim 1, wherein the platelet-rich plasma and the thrombin solution in the step (4) are mixed at a volume ratio of 10:1 to prepare a platelet-rich gel.
9. A platelet rich gel obtained by the method according to any one of claims 1 to 8.
10. Use of the platelet rich gel of claim 9 for the treatment of diabetic ulcers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910984321.2A CN110664735A (en) | 2019-10-16 | 2019-10-16 | Platelet-rich gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910984321.2A CN110664735A (en) | 2019-10-16 | 2019-10-16 | Platelet-rich gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110664735A true CN110664735A (en) | 2020-01-10 |
Family
ID=69082759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910984321.2A Pending CN110664735A (en) | 2019-10-16 | 2019-10-16 | Platelet-rich gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110664735A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111760064A (en) * | 2020-08-25 | 2020-10-13 | 重庆大学附属肿瘤医院 | Dressing for treating diabetic foot and preparation method thereof |
| CN111773250A (en) * | 2020-05-28 | 2020-10-16 | 东南大学 | Platelet gel supernatant, preparation method and application thereof |
| CN113546218A (en) * | 2021-07-21 | 2021-10-26 | 南昌大学第二附属医院 | Method and formula for in-situ construction of PRP gel tissue engineering compound for different tissue regeneration |
| CN113817712A (en) * | 2021-10-09 | 2021-12-21 | 珠海朗泰生物科技有限公司 | Process for preparing thrombin |
| CN114887113A (en) * | 2022-05-25 | 2022-08-12 | 中南大学湘雅三医院 | Preparation method and application of Gelma gel loaded with platelet membrane coated cerium oxide |
| CN115068691A (en) * | 2022-06-10 | 2022-09-20 | 华中科技大学 | Injectable bioactive hydrogel and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212125A (en) * | 2013-04-01 | 2013-07-24 | 浙江康慈医疗科技有限公司 | Method and special equipment for rapidly extracting platelet-rich high-concentration blood plasma |
| CN105505855A (en) * | 2016-02-04 | 2016-04-20 | 关志广 | Preparation method of autologous epidermic cell APG gel with multiplication capacity |
| WO2018067341A1 (en) * | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
| CN108295323A (en) * | 2018-02-08 | 2018-07-20 | 中国人民解放军陆军军医大学第附属医院 | The preparation method of rich platelet gel |
-
2019
- 2019-10-16 CN CN201910984321.2A patent/CN110664735A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212125A (en) * | 2013-04-01 | 2013-07-24 | 浙江康慈医疗科技有限公司 | Method and special equipment for rapidly extracting platelet-rich high-concentration blood plasma |
| CN105505855A (en) * | 2016-02-04 | 2016-04-20 | 关志广 | Preparation method of autologous epidermic cell APG gel with multiplication capacity |
| WO2018067341A1 (en) * | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
| CN108295323A (en) * | 2018-02-08 | 2018-07-20 | 中国人民解放军陆军军医大学第附属医院 | The preparation method of rich platelet gel |
Non-Patent Citations (2)
| Title |
|---|
| 王庆敏等: "血小板添加液保存单采血小板的研究", 《临床输血与检验》 * |
| 钟晓卫等: "自体富血小板凝胶在糖尿病血运重建患者中的疗效评价", 《四川医学》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773250A (en) * | 2020-05-28 | 2020-10-16 | 东南大学 | Platelet gel supernatant, preparation method and application thereof |
| CN111760064A (en) * | 2020-08-25 | 2020-10-13 | 重庆大学附属肿瘤医院 | Dressing for treating diabetic foot and preparation method thereof |
| CN113546218A (en) * | 2021-07-21 | 2021-10-26 | 南昌大学第二附属医院 | Method and formula for in-situ construction of PRP gel tissue engineering compound for different tissue regeneration |
| CN113817712A (en) * | 2021-10-09 | 2021-12-21 | 珠海朗泰生物科技有限公司 | Process for preparing thrombin |
| CN113817712B (en) * | 2021-10-09 | 2023-11-14 | 珠海朗泰生物科技有限公司 | Process for preparing thrombin |
| CN114887113A (en) * | 2022-05-25 | 2022-08-12 | 中南大学湘雅三医院 | Preparation method and application of Gelma gel loaded with platelet membrane coated cerium oxide |
| CN114887113B (en) * | 2022-05-25 | 2023-04-25 | 中南大学湘雅三医院 | Preparation method and application of Gelma gel of platelet-supported film-coated cerium oxide |
| CN115068691A (en) * | 2022-06-10 | 2022-09-20 | 华中科技大学 | Injectable bioactive hydrogel and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110664735A (en) | Platelet-rich gel and preparation method thereof | |
| Skórkowska-Telichowska et al. | The local treatment and available dressings designed for chronic wounds | |
| CN103041438B (en) | Moist antibacterial hydrogel dressing for curing diabetic foot ulcer | |
| US4414202A (en) | Composition for treatment of wounds | |
| US20060018955A1 (en) | Method for preparing medical dressings | |
| AU2020101591A4 (en) | A thermosensitive gel, preparation method and application thereof | |
| CN111228040A (en) | Absorbable anti-adhesion dressing and preparation method thereof | |
| JPH07508275A (en) | Thrombin blood fraction used in medical procedures | |
| KR20010071577A (en) | Application for Utility Patent for Improved Enriched Platelet Wound Healant | |
| CN110613680A (en) | Preparation method of gel preparation for wound | |
| CN108478846A (en) | A kind of medical hemostatic antiseptic dressing and preparation method thereof | |
| CN112402364B (en) | Umbilical cord mesenchymal stem cell-platelet-rich plasma-containing composite repair gel for injection | |
| Deng et al. | Chronic wound treatment with high-density nanofat grafting combined with negative pressure wound therapy | |
| CN112999410B (en) | Nano oxygenated hydrogel healing-promoting dressing containing perfluorodecalin and preparation method and application thereof | |
| CN110721343A (en) | GFG gel capable of repairing depressed or atrophic scars, and preparation method and application thereof | |
| RU2543344C2 (en) | Method of treating trophic ulcers | |
| Thomas | 12 Wound Dressings | |
| CN111000794B (en) | Bletilla polysaccharide/bioglass temperature-sensitive gel and preparation method and application thereof | |
| RU2616239C2 (en) | Method for erosive and ulcerative skin lesions treatment | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| WO2017082441A1 (en) | Veterinary medicinal composition for treatment of wound of animal comprising activated platelet-rich plasma as active ingredient | |
| EP0034504B1 (en) | Combinations for the treatment of wounds | |
| CN107468708A (en) | A kind of preparation method of Stem Cell Activity factor gel and the application in Hard agglut wound treatment | |
| CN106562953A (en) | Application of hydroxysafflor yellow A in preparing medicine for treating diabetic foot ulceration, medicine and medicine preparation method | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200110 |